Leerink Swann Boosts GW Pharmaceuticals PLC- (GWPH) Price Target to $157.00

GW Pharmaceuticals PLC- (NASDAQ:GWPH) had its target price boosted by equities researchers at Leerink Swann from $153.00 to $157.00 in a note issued to investors on Tuesday. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Swann’s price target points to a potential upside of 18.89% from the stock’s current price.

A number of other research analysts also recently issued reports on GWPH. Zacks Investment Research raised shares of GW Pharmaceuticals PLC- from a “sell” rating to a “hold” rating in a research report on Tuesday, January 30th. Cantor Fitzgerald restated a “buy” rating and set a $192.00 target price (down previously from $208.00) on shares of GW Pharmaceuticals PLC- in a report on Monday. BidaskClub cut shares of GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th. Goldman Sachs Group upgraded shares of GW Pharmaceuticals PLC- from a “neutral” rating to a “buy” rating and set a $174.00 target price on the stock in a report on Thursday, December 14th. Finally, Bank of America dropped their target price on shares of GW Pharmaceuticals PLC- from $160.00 to $158.00 and set a “buy” rating on the stock in a report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $146.38.

GW Pharmaceuticals PLC- (NASDAQ GWPH) opened at $132.06 on Tuesday. The company has a current ratio of 7.59, a quick ratio of 7.47 and a debt-to-equity ratio of 0.02. The stock has a market cap of $3,350.00, a price-to-earnings ratio of -14.80 and a beta of 2.50. GW Pharmaceuticals PLC- has a 1 year low of $92.65 and a 1 year high of $143.37.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported ($2.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($2.03) by ($0.40). The company had revenue of $7.73 million for the quarter, compared to analysts’ expectations of $2.18 million. GW Pharmaceuticals PLC- had a negative net margin of 1,357.98% and a negative return on equity of 53.20%. equities research analysts predict that GW Pharmaceuticals PLC- will post -7.76 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in GWPH. IHT Wealth Management LLC boosted its holdings in shares of GW Pharmaceuticals PLC- by 18.0% during the 2nd quarter. IHT Wealth Management LLC now owns 656 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 100 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of GW Pharmaceuticals PLC- by 10.7% during the 2nd quarter. Advisor Group Inc. now owns 1,500 shares of the biopharmaceutical company’s stock valued at $130,000 after buying an additional 145 shares in the last quarter. Van Hulzen Asset Management LLC bought a new stake in shares of GW Pharmaceuticals PLC- during the 3rd quarter valued at $205,000. Ameriprise Financial Inc. boosted its holdings in shares of GW Pharmaceuticals PLC- by 8.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 162 shares in the last quarter. Finally, State Street Corp bought a new stake in shares of GW Pharmaceuticals PLC- during the 2nd quarter valued at $212,000. Hedge funds and other institutional investors own 74.49% of the company’s stock.

WARNING: “Leerink Swann Boosts GW Pharmaceuticals PLC- (GWPH) Price Target to $157.00” was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2018/02/08/leerink-swann-boosts-gw-pharmaceuticals-plc-gwph-price-target-to-157-00.html.

GW Pharmaceuticals PLC- Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit